Annual Sales of Lipitor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Sales projections: What is the expected Lipitor revenue path over 5-10 years under generic price compression? Featured snippet answer: Lipitor sales over the next decade are expected to track a declining brand share multiplied by net price that continues to compress toward generic equivalents, while total atorvastatin class demand is broadly … Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Humira, introduced by AbbVie in 2003, is expected to remain the drug with the highest lifetime revenue through 2024. Keytruda follows with a lifetime revenue of 213 billion U.S. dollars. Worldwide revenue of Pfizer's Lipitor from 2003 to 2019 (in million U.S. dollars) Pfizer's Lipitor revenue worldwide 2003-2019 Ask AI Premium | Feb 28, 2020 NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman and chief executive … Drug sales of Top 20 best-selling drugs and pharma insights from the world's largest selling pharmaceuticals in 2020 A drug that is able to generate at least one billion in sales annually is defined as a blockbuster drug. Lipitor (atorvastatin) was discovered at Parke-Davis and launched in 1997, the fifth statin on the market. It became the world's best-selling drug, with sales peaking at US$12.9 billion in 2006, until Humira overtook its lifetime sales in 2020. Also presented below is a comparison of full-year 2019 results excluding the revenue contribution from the Consumer Healthcare (1) segment to Pfizer's 2020 Total Company (4) financial guidance for revenues and Adjusted diluted EPS (3) at 2019 foreign exchange rates and at mid-January 2020 foreign exchange rates. Counting up 25 years' worth of sales, Pfizer's Lipitor remains the U.S.' best-selling drug over the past two and a half decades, but AbbVie's Humira will soon catch up. (Pixabay/CC0) Take a look … Indeed, Pfizer's business model has relied on the huge profits from Lipitor and a few other blockbuster drugs. But things are set to change. The patent for Lipitor expired on Nov 30. Pfizer will undoubtedly feel the loss of Lipitor sales. It has been planning for this schismatic change for several years. A striking graph of those results helped Lipitor sales representatives turn it into the world's best-selling drug ever, with more than $125 billion in sales over 14 1/2 years. Explore the best-selling drugs US pharma produced over 25 years, from Lipitor to Humira, and what clinical research made each blockbuster possible. Apache/2.4.52 (Ubuntu) Server at fomatmedical.com Port 80 Lipitor was approved by the government in 1997, and while under patent protection it was the highest-selling drug of all time with worldwide sales of more than US$12 billion a year. Lipitor, the cholesterol-lowering medication that has become the gold standard of statins, continues to generate roughly $2 billion per year in sales for Pfizer, even though its patent expired eight years ago. The big picture: Almost all of Pfizer's Lipitor sales now come from China and other emerging markets. But Lipitor's ability to remain a blockbuster drug, even with so many generic … Dose offers science-backed liquid supplements to support your body's health core systems and overall wellness with proven ingredients. Atorvastatin, sold under the brand name Lipitor among others, is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. [7] For the prevention of cardiovascular disease, statins are a first-line treatment in reducing cholesterol. [7] It is taken by mouth. [7] Common side effects may include diarrhea, heartburn, nausea, muscle pain … LIPITOR Market size is expected to reach USD 937.7 Mn by 2033 from USD 1,386.6 Mn in 2026, exhibiting a CAGR of -5.2% during the forecast period 2026-2033 Clearly this analysis is distorted to some extent by the earlier launch date of Lipitor (in 1996). However, if we look at cumulative sales during the first 10 years of availability, Lipitor still … These 15 all-time best-selling prescription drugs are in rarified air, churning out tens of billions of dollars and affecting millions of people around the world. Pfizer retained approximately 70% of the profits from Watson's generic atorvastatin sales. The economic consequence: during Ranbaxy's 180-day exclusivity window, Pfizer was effectively competing against itself (Ranbaxy generic) with its own authorized generic (Watson label), while also defending the brand (Lipitor) with co-pay support. Over the past decade, Lipitor was the most widely used branded prescription treatment for lowering blood cholesterol levels. Global Lipitor sales peaked at $13 billion in 2006 and has been on a … Two new generic brands of cholesterol-lowering medication threaten sales to Pfizer's number one selling drug — Lipitor. Good news? More people can afford it now. Lipitor is a medication from Pfizer that helps lower cholesterol, but a delay in authorizing generic versions led to higher costs. Some patients who've taken the drug later developed Type 2 diabetes, leading to health concerns and lawsuits. Atorvastatin Market size was valued at $ 0.089 Billion in 2026 & is estimated to reach $ 0.15 Billion by 2032, exhibiting a CAGR of 7.71% from 2026-2032 In the time of patent loss, between 2011 and 2012, Pfizer's revenue through Lipitor declined by some 60 percent. But both Humira and Lipitor are still the leading drugs by lifetime sales worldwide. Learn about LIPITOR® (atorvastatin calcium), a prescription medication that may help your condition. Read the Important Safety Information. Pfizer is once again confronting a major patent cliff, similar to the one it faced in the early 2010s when it lost exclusivity on several high-revenue drugs including Lipitor, Protonix, and Geodon. During that period, Lipitor's annual sales declined significantly from a peak of $12.9 billion following the entry of… Atorvastatin market size reached $14.48 billion in 2026 and is expected to grow to $20.64 billion by 2030 at a 9.3% CAGR. Major players: Zydus Lifesciences, Pfizer Inc., Viatris Inc. The hypercholesterolemia segment held the largest share of the global Atorvastatin Calcium market in 2025, capturing 45.9% of total revenue. The increasing prevalence of elevated cholesterol levels, driven by sedentary lifestyles, obesity, unhealthy dietary habits, and aging populations, has significantly contributed to the segment's leadership. In fact, at the current rate, Humira could easily dethrone Lipitor next year. After all, it brought in nearly $20 billion worldwide last year, and U.S. sales growth is softening the EU biosimilars … So, this year, it has snatched the crown for the industry's most successful drug from Lipitor (atorvastatin), a cholesterol-lowering drug that racked up ~$160 billion in full-year sales in 23 … A striking graph of those results helped Lipitor sales representatives turn it into the world's best-selling drug ever, with more than $125 billion in sales over 14 ½ years. Atorvastatin drug usage statistics for the United States (2014 – 2024). Statistics include drug synonyms and therapeutic classes, including: Atorvastatin Calcium, Atorvastatin Calcium Anhydrous, Atorvastatin Calcium Propylene Glycol Solvate, Atorvastatin Calcium Trihydrate, Atorvastatin, Atorvaliq, Lipitor, HMG-CoA Reductase Inhibitor. FDA provides a searchable list of recalled products. Drug recalls are actions taken by a firm to remove a product from the market. The Lipitor Market, valued at USD 1.38B in 2026, is projected to reach USD 2.03B by 2034, growing at a 4.9% CAGR. Lipitor, Protonix, and the Pfizer Product Line Between 2010 and 2012, drugs that make up 42% of Pfizer's pharmaceutical revenue, including Lipitor, Protonix (pantoprazole) and Geodon (ziprasidone), will all have lost patent protection.
